Ann Beliën is the founder and CEO of Rejuvenate Biomed. Rejuvenate Biomed studies the biology of aging and is repurposing prescription drugs with the aim to delay the onset of multiple age-related diseases. One of the portfolio products is focusing on sarcopenia as an entry into the space of healthy aging. Ann has over 17 years of experience in drug development from bench to market, which she acquired at Johnson & Johnson throughout multiple international assignments (US, NL, BE).  She joined Johnson & Johnson in 2000, after a postdoc at ETH, Zürich, Switzerland. She holds a PhD from the University of Irchel, Zürich, Switzerland and a master’s degree from the Free University of Brussels (VUB), Belgium.